Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer’s Disease (NCT01626391) (2013)

Government Record · TauRx Therapeutics Ltd (sponsor); ClinicalTrials.gov record · March 2013

TauRx Therapeutics Ltd (sponsor), 2013-03: Industry safety/interaction study of TRx0237 added to cholinesterase inhibitors or memantine, started September 2012 with 9 participants enrolled, terminated in March 2013 for stated administrative reasons.

This study has been terminated for administrative reasons only.

TauRx Therapeutics Ltd (sponsor), 2013-03: Industry safety/interaction study of TRx0237 added to cholinesterase inhibitors or memantine, started September 2012 with 9 participants enrolled, terminated in March 2013 for stated administrative reasons. Record field (whyStopped) transcribed from the ClinicalTrials.gov API v2 record; confidence MEDIUM per rules for registry fields. No results posted. Bearing is CONTRADICTS only in the weak sense that the drug-interaction question was never answered by a completed trial – it is a terminated registration, not a negative result. hosting=LINK because the ClinicalTrials.gov study record is HTML-only (no PDF); copyright remains US Federal Public Domain. The record text was read from https://clinicaltrials.gov/api/v2/studies/NCT01626391 and the study page is JavaScript-rendered. Also filed as MTK-46 (claims C14, C9).